扩大艾滋病毒/艾滋病治疗规模:从多药耐药结核病中吸取教训
Rajesh Gupta1, Alexander Irwin, Mario C Raviglione
1Office of the Director General, WHO, Geneva, Switzerland. guptara@who.int
Lancet (London, England)
|January 31, 2004
概括
从扩大多药耐药结核病治疗的经验,特别是绿灯委员会机制的经验教训,为扩大发展中国家抗逆转录病毒艾滋病治疗计划提供了宝贵的见解.
科学领域:
- 全球健康 全球健康
- 传染病管理 传染病管理
- 公共卫生政策 公共卫生政策
背景情况:
- 联合国发起了"三倍五"目标,到2005年为发展中国家的300万人提供抗逆转录病毒艾滋病治疗.
- 在资源有限的环境中,扩大艾滋病毒/艾滋病治疗面临重大挑战.
- 多药耐药结核病 (MDR-TB) 治疗扩展提供了一个相关的案例研究.
研究的目的:
- 通过绿灯委员会 (GLC) 机制,分析从扩大MDR-TB治疗中吸取的教训.
- 确定这些教训如何为艾滋病毒/艾滋病治疗计划的扩展提供信息和改进.
- 为建立可持续的抗逆转录病毒治疗计划提供见解.
主要方法:
- 审查绿灯委员会 (GLC) 机制在扩大MDR-TB治疗方面的经验.
- 分析GLC在政策制定,药物采购和卫生系统加强等领域的成功和挑战.
- 将这些发现应用于联合国关于艾滋病治疗的"三对五"倡议.
主要成果:
- 通过GLC机制,在政策制定,药物采购和对MDR-TB的合理药物使用方面取得了进展.
- 加强卫生系统一直是GLC扩张工作的一个关键成果.
- 全球治疗协会的经验凸显了大规模治疗计划实施的促进者和障碍.
结论:
- 绿灯委员会的经验为成功扩大艾滋病毒/艾滋病治疗提供了有价值的框架和实际见解.
- 可持续的艾滋病毒/艾滋病治疗计划可以从MDR-TB管理中吸取的经验教训中受益,特别是在多利益相关者合作和卫生系统加强方面.
- 从MDR-TB控制中调整策略可以提高全球抗逆转录病毒疗法倡议的有效性和影响力.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...


